Recent advances in the management of renal cell carcinoma

por Molina, Ana M., Nanus, David M.
Publicado 2016

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

por Molina, Ana M., Ginsberg, Michelle S., Motzer, Robert J.
Publicado 2010

Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment Strategies

por Sankin, Alexander, Hakimi, A. Ari, Hsieh, James J., Molina, Ana M.
Publicado 2015

Multifractal Properties of Time Series of Synthetic Earthquakes Obtained from a Spring-Block Model

por Aguilar-Molina, Ana M., Muñoz-Diosdado, Alejandro, Martínez, Alfredo Salinas, Angulo-Brown, Fernando
Publicado 2023

Neutrophil Chemokines Secreted by Tumor Cells Mount a Lung Antimetastatic Response during Renal Cell Carcinoma Progression

por López-Lago, Miguel A., Posner, Shai, Thodima, Venkata J., Molina, Ana M., Motzer, Robert J., Chaganti, RSK
Publicado 2012

Volatile Transference and Antimicrobial Activity of Cheeses Made with Ewes’ Milk Fortified with Essential Oils

por Licon, Carmen C., Moro, Armando, Librán, Celia M., Molina, Ana M., Zalacain, Amaya, Berruga, M. Isabel, Carmona, Manuel
Publicado 2020

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

por Molina, Ana M., Hutson, Thomas E., Nosov, Dmitry, Tomczak, Piotr, Lipatov, Oleg, Sternberg, Cora N., Motzer, Robert, Eisen, Tim
Publicado 2018

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

por Molina, Ana M., Hutson, Thomas E., Larkin, James, Gold, Anne M., Wood, Karen, Carter, Dave, Motzer, Robert, Michaelson, M. Dror
Publicado 2013

Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma

por van der Mijn, Johannes C., Fu, Leiping, Khani, Francesca, Zhang, Tuo, Molina, Ana M., Barbieri, Christopher E., Chen, Qiuying, Gross, Steven S., Gudas, Lorraine J., Nanus, David M.
Publicado 2019

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

por Carlo, Maria I., Molina, Ana M., Lakhman, Yulia, Patil, Sujata, Woo, Kaitlin, DeLuca, John, Lee, Chung-Han, Hsieh, James J., Feldman, Darren R., Motzer, Robert J., H. Voss, Martin
Publicado 2016

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

por Vlachostergios, Panagiotis J., Niaz, Muhammad Junaid, Sun, Michael, Mosallaie, Seyed Ali, Thomas, Charlene, Christos, Paul J., Osborne, Joseph R., Molina, Ana M., Nanus, David M., Bander, Neil H., Tagawa, Scott T.
Publicado 2021

Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)

por Marciscano, Ariel E., Wolfe, Sydney, Zhou, Xi Kathy, Barbieri, Christopher E., Formenti, Silvia C., Hu, Jim C., Molina, Ana M., Nanus, David M., Nauseef, Jones T., Scherr, Douglas S., Sternberg, Cora N., Tagawa, Scott T., Nagar, Himanshu
Publicado 2023

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, p...

por George, Daniel J, Spigel, David R, Gordan, Lucio N, Kochuparambil, Samith T, Molina, Ana M, Yorio, Jeff, Rezazadeh Kalebasty, Arash, McKean, Heidi, Tchekmedyian, Nishan, Tykodi, Scott S, Zhang, Joshua, Askelson, Margarita, Johansen, Jennifer L, Hutson, Thomas E
Publicado 2022

Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series

por van der Mijn, Johannes C., Al Hussein Al Awamlh, Bashir, Islam Khan, Aleem, Posada-Calderon, Lina, Oromendia, Clara, Fainberg, Jonathan, Alshak, Mark, Elahjji, Rahmi, Pierce, Hudson, Taylor, Benjamin, Gudas, Lorraine J., Nanus, David M., Molina, Ana M., Del Pizzo, Joseph, Scherr, Douglas S.
Publicado 2019

The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy

por van der Mijn, Johannes C., Eng, Kenneth W., Chandra, Pooja, Fernandez, Evan, Ramazanoglu, Sinan, Sigaras, Alexandros, Oromendia, Clara, Gudas, Lorraine J., Tagawa, Scott T., Nanus, David M., Faltas, Bishoy F., Beltran, Himisha, Sternberg, Cora N., Elemento, Olivier, Sboner, Andrea, Mosquera, Juan Miguel, Molina, Ana M.
Publicado 2022

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

por Emamekhoo, Hamid, Olsen, Mark R., Carthon, Bradley C., Drakaki, Alexandra, Percent, Ivor J., Molina, Ana M., Cho, Daniel C., Bendell, Johanna C., Gordan, Lucio N., Rezazadeh Kalebasty, Arash, George, Daniel J., Hutson, Thomas E., Arrowsmith, Edward R., Zhang, Joshua, Zoco, Jesus, Johansen, Jennifer L., Leung, David K., Tykodi, Scott S.
Publicado 2021

Common germline-somatic variant interactions in advanced urothelial cancer

por Vosoughi, Aram, Zhang, Tuo, Shohdy, Kyrillus S., Vlachostergios, Panagiotis J., Wilkes, David C., Bhinder, Bhavneet, Tagawa, Scott T., Nanus, David M., Molina, Ana M., Beltran, Himisha, Sternberg, Cora N., Motanagh, Samaneh, Robinson, Brian D., Xiang, Jenny, Fan, Xiao, Chung, Wendy K., Rubin, Mark A., Elemento, Olivier, Sboner, Andrea, Mosquera, Juan Miguel, Faltas, Bishoy M.
Publicado 2020

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

por Robinson, Brian D., Vlachostergios, Panagiotis J., Bhinder, Bhavneet, Liu, Weisi, Li, Kailyn, Moss, Tyler J., Bareja, Rohan, Park, Kyung, Tavassoli, Peyman, Cyrta, Joanna, Tagawa, Scott T., Nanus, David M., Beltran, Himisha, Molina, Ana M., Khani, Francesca, Miguel Mosquera, Juan, Xylinas, Evanguelos, Shariat, Shahrokh F., Scherr, Douglas S., Rubin, Mark A., Lerner, Seth P., Matin, Surena F., Elemento, Olivier, Faltas, Bishoy M.
Publicado 2019

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience

por Costello, Brian A., Bhavsar, Nrupen A., Zakharia, Yousef, Pal, Sumanta K., Vaishampayan, Ulka, Jim, Heather, Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che-Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Mardekian, Jack, Borham, Azah, George, Daniel J., Harrison, Michael R.
Publicado 2022

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)

por Harrison, Michael R., Costello, Brian A., Bhavsar, Nrupen A., Vaishampayan, Ulka, Pal, Sumanta K., Zakharia, Yousef, Jim, Heather S. L., Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che‐Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Inman, Brant A., Mardekian, Jack, Borham, Azah, George, Daniel J.
Publicado 2021